medigraphic.com
ISSN 1561-3011 (Electronic)

2014, Number 1

<< Back Next >>

Rev Cubana Invest Bioméd 2014; 33 (1)

DNA methylation and implications in carcinogenesis

Uribe YDF, Fabián M Cortes Mancera

Language: Spanish
References: 39
Page: 81-93
PDF size: 593.86 Kb.


ABSTRACT

Cancer has become one of the main public health problems worldwide, not only for its incidence, but also due to its high morbidity and mortality. Only in 2008, an estimated 12 million new cancer cases were diagnosed, with 7 million deaths and 25 million people living with the disease. On a cellular and molecular level, cancer is defined as an alteration in the mechanisms regulating cell division. Epigenetics is the study of inheritable changes affecting the gene expression pattern in these mechanisms, which are not a consequence of alterations in the nucleotide sequence of the gene (mutations) or its regulatory sequences (promoters). Among these changes, DNA methylation has been characterized most accurately. It has been associated with the silencing or overexpression of genes performing a key role in regulating the start and progress of cancer, such as the genes involved in the Wnt/β-catenin signaling pathway. Understanding the steps involved in the start and establishment of gene expression alterations mediated by epigenetic phenomena, will make it possible to develop therapies aimed at key components of this process. The present study is an analysis of some epigenetic mechanisms, their effect on gene expression regulation, and their role in carcinogenesis.


REFERENCES

  1. Boyle P, Levin B, Editores. World Cancer Report 2008. Lyon, Francia: International Agency for Research on Cancer; 2008:

  2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr [accessed on 24/10/2012].

  3. Ting AH, McGarvey KM, Baylin SB. The cancer epigenome - components and functional correlates. Genes Dev. 2006;20:3215-31.

  4. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci. 2006;31(2):89-97.

  5. Feinberg AP The epigenetics of cancer etiology. Semin Cancer Biol. 2004;14:427-32.

  6. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol. 2005;2(S1):S4-S11.

  7. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007;8(4):286-98.

  8. Esteller M. Epigenetics in Cancer. N Engl J Med. 2008;358:1148-59.

  9. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, et al. Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades. Oncotarget. 2012;3(9):954-87.

  10. Ying Y, Qian T. Epigenetic disruption of the WNT/β-catenin signaling pathway in human cancers. Epigenetics. 2009;4:5,307-12.

  11. Aguilera O, Muñoz A, Esteller M, Fraga MF. Epigenetic alterations of the Wnt/betacatenin pathway in human disease. Endocr Metab Immune Disord Drug Targets. 2007;7(1):13-21.

  12. Brembeck FH, Rosário M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of β-catenin. Curr Opin Genet Dev. 2006;16:51-9.

  13. White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology. 2012;142(2):219-32.

  14. Morin PJ, Sparks AB, Korinek V, Barrer N, Clevers H, Vogelstein B, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997;275:1787-90.

  15. Ishizaki Y, Ikeda S, Fujimori M, Shimizu Y, Kurihara T, Itamoto T, et al. Immunohistochemical analysis and mutational analyses of β-catenin, axin family and APC genes in hepatocellular carcinomas. Int J Oncol. 2004;24(5):1077-83.

  16. Khare SP, Habib F, Sharma R, Gadewal N, Gupta S, Galande S. Hlstome- a relational knowledgebase of human histone proteins and histone modifying enzymes. Nucleic Acids Res. 2012 Jan;40 s(Database issue):D337-42.

  17. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006;6:107-116.

  18. Plath K, Fang J, Mlynarczyk-Evans SK, Cao R, Worringer KA, Wang H, et al. Role of Histone H3 Lysine 27 Methylation in X Inactivation. Science. 2003;300:131-5.

  19. Fahrner JA, Eguchi S, Herman JG, Baylin SB. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res. 2002;62:7213-8.

  20. Bachman KE, Park BH, Rhee I, Rajagopalan H, Herman JG, Baylin SB, et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell. 2003;3:89-95.

  21. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004;4:143-53.

  22. Holm TM, Jackson-Grusby L, Brambrink T, Yamada Y, Rideout WM, Jaenisch R. Global loss of imprinting leads to widespread tumorigenesis in adult mice. Cancer Cell. 2005;8(4):275-85.

  23. Yamada Y, Jackson-Grusby L, Linhart H, Meissner A, Eden A, Lin H, et al. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. PNAS. 2005;2(38):13580-5.

  24. Igarashi S, Suzuki H, Niinuma T, Shimizu H, Nojima M, Iwaki H, et al. A Novel Correlation between LINE-1 Hypomethylation and the Malignancy of Gastrointestinal Stromal Tumors. Clin Cancer Res. 2010;16:5114-23.

  25. Cho NY, Kim BH, Choi M, Yoo EJ, Moon KC, Cho YM, et al. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol. 2007; 211:269-277.

  26. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT, Schernhammer ES, et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst. 2008;100:1734-8.

  27. Pattamadilok J, Huapai N, Rattanatanyong P, Vasurattana A, Triratanachat S, Tresukosol D, et al. LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18:711-7.

  28. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Cervantes F, Sanchez J, Garate L, et al. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene. 2005;24:7213-23.

  29. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics. 2009;1(2):239-59.

  30. Katoh H, Shibata T, Kokubu A, Ojima H, Fukayama M, Kanai Y, et al. Epigenetic Instability and Chromosomal Instability in Hepatocellular Carcinoma. Am J Pathol. 2006;168(4):1375-83.

  31. Yang B, Guo M, Herman JG, Clark DP. Aberrant Promoter Methylation Profiles of Tumor Suppressor Genes in Hepatocellular Carcinoma. Am J Pathol. 2003;163(3):1101-7.

  32. Prasad CP, Mirza S, Sharma G, Prashad R, DattaGupta S, Rath G, et al. Epigenetic alterations of CDH1 and APC genes: relationship with activation of Wnt/beta-catenin pathway in invasive ductal carcinoma of breast. Life Sci. 2008;83(9-10):318-25.

  33. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci. 2003 Jul 1;116(Pt 13):2627-34.

  34. Taniguchi H, Yamamoto H, Hirata T, Miyamoto N, Oki M, Nosho K, et al. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene. 2005;24:7946-52.

  35. Veeck J, Wild PJ, Fuchs T, Schüffler PJ, Hartmann A, Knüchel R, et al. Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer. BMC Cancer. 2009 Jul;(9):217.

  36. Kaur P, Mani S, Cros MP, Scoazec JY, Chemin I, Hainaut P, et al. Epigenetic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular carcinoma. Tumour Biol. 2012;33(2):325-36.

  37. Fisher DA, Kivimäe S, Hoshino J, Suriben R, Martin PM, Baxter N, et al. Three Dact gene family members are expressed during embryonic development and in the adult brains of mice. Dev Dyn. 2006;235(9):2620-30.

  38. Wong HC, Bourdelas A, Krauss A, Lee HJ, Shao Y, Wu D, et al. Direct Binding of the PDZ Domain of Dishevelled to a Conserved Internal Sequence in the C-Terminal Region of Frizzled. Mol Cell. 2003;12:1251-60.

  39. Jiang X, Tan J, Li J, Kivimäe S, Yang X, Zhuang L, et al. DACT3 is an epigenetic regulator of Wnt/β-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell. 2008;13(6):529-41.




2020     |     www.medigraphic.com